Oral Ketamine vs Placebo in Patients With Cancer-Related Neuropathic Pain: A Randomized Clinical Trial

Ketamine hydrochloride is used as an adjuvant treatment for cancer-related neuropathic pain, but evidence of its effectiveness is limited. Findings of a large trial investigating the use of ketamine for general cancer pain were negative, but the population studied did not specifically have neuropathic pain. A randomized trial of oral ketamine for cancer-related neuropathic pain has been called for, and the present trial addresses that need.

Methods | A multicenter, double-blind randomized clinical trial of oral ketamine vs placebo was conducted in the United Kingdom cities of Edinburgh, Glasgow, Nottingham, and Lancashire in adults with cancer-related neuropathic pain, which was defined using set criteria (Leeds Assessment of Neuropathic Symptoms and Signs). Patients had previously been treated with adjuvant analgesics for neuropathic pain, which had been ineffective or suboptimal. Preexisting analgesia was continued throughout the trial. Patients were centrally randomized using minimization, then ketamine or placebo was titrated across 2 weeks to an effective and tolerable dosage (Figure). The starting dosage was 40 mg/d, with a maximum dosage of 400 mg/d. Patients continued to receive a stable dosage for 16 days. Patients who did not experience an analgesic benefit were withdrawn from the trial.

Figure. CONSORT Study Flow Diagram

Among the 107 patients randomized to ketamine, the median (interquartile range [IQR]) time spent in the titration phase for the 58 patients who experienced treatment failure and were excluded was 14 (14-14) days; range, 7 to 28 days. Of the 49 patients who entered the pain-control maintenance phase, the median (IQR) time spent in the titration phase was 14 (14-15) days; range, 8 to 21 days. Among the 107 patients randomized to placebo, the median (IQR) time spent in the titration phase was 14 (14-15) days; range, 8 to 21 days. Among the 50 patients who entered the pain-control maintenance phase, the median (IQR) time spent in the titration phase was 14 (12.5-14.0) days; range, 0 to 22 days. Of the 50 patients who entered the pain-control maintenance phase, the median (IQR) time spent in the titration phase was 14 (14-15) days; range, 5 to 20 days. MEDD indicates morphine-equivalent daily dose.
study. The study was approved by the West of Scotland Multicentre Research Ethics Committee (the full trial protocol is available in the Supplement; isrctn.org Identifier: ISRCTN49116945 and clinicaltrialsregister.eu Identifier: 2007-002080-27), and participants provided written informed consent.

The primary end point was duration of analgesic benefit, defined as an improvement of 5 points or more in the index pain score (using the Sensory Component of the Short Form McGill Pain Questionnaire), compared with the baseline score during the 16 days of receiving a stable dosage of ketamine or placebo. Patients in whom titration failed were considered to have a duration of 0 days. Maintenance of analgesic benefit was considered to have failed in patients whose opioid dosage increased during this time. Secondary end points included mean and worst pain; mood (Hospital Anxiety and Depression Score, a self-administered anxiety and depression screening tool for use in nonpsychiatric patients. The tool has 14 items, which focus on the emotional and cognitive aspects of each aspect. Each item is scored from 0 to 3 for a combined maximum of 21 for each aspect, with higher scores reflecting a higher symptom load); mean change in global distress in the last 24 hours (National Comprehensive Cancer Network Distress Thermometer, which uses a scale of 0 to 10, where 0 is no distress and 10 is extreme distress); quality of life (EuroQol Thermometer, which uses a scale of 0 to 100); and serious adverse events (National Cancer Institute, Common Toxicity Criteria for Adverse Events version 3.0, which provides clinicians with descriptive terminology for reporting adverse events. Each adverse event is graded on a scale of 1 to 5, with higher grades representing greater severity).

An intention-to-treat approach was used, with a sample size of 107 patients per arm providing 80% or greater power to detect an improvement in the duration of analgesic benefit while receiving ketamine corresponding to a 20% increase in patients in whom analgesic benefit was maintained at 16 days (maximum hazard ratio [HR], 0.58). To compare duration of analgesic benefit, we used Cox proportional hazards regression with a confirmatory log-rank test. Secondary end points were analyzed using parametric and nonparametric methods. Quality of life data were analyzed by calculating the mean of the area under the curve over the time in the study after adjusting for the baseline value. All P values are 2-tailed, and P < .05 was statistically significant.

Results | Two hundred fourteen patients (median [IQR] age, 58 [51.66] years; 141 [65.8%] female) were randomized, with comparable demographic features between arms (Figure). A variety of cancer types were represented; however, in 160 patients (74.7%) the cancer was in remission, and most of these patients had chronic, chemotherapy-induced, neuropathic pain. Two hundred nine patients (97.6%) were following treatment regimens for neuropathic pain. Data on duration of neuropathic pain were not collected. The median morphine-equivalent daily dose for both arms was 0 mg. There was no difference in the duration of analgesic benefit between arms as assessed by the adjusted (minimization factors) Cox proportional hazards model (ketamine to placebo HR, 0.95 [95% CI, 0.70-1.29]; P = .75), supported by the log-rank test (P = .69). The median duration of analgesic benefit was 0 days (95% CI, 0-1 day) for ketamine and 0 days (95% CI, 0-4 days) for placebo. To illustrate, 34 of 107 patients (31.8%) receiving ketamine vs 39 of 107 (36.4%) receiving placebo maintained analgesic benefit at day 4 of the stable dosage (95% CI for
difference, −17% to 8%). Corresponding figures at day 16 were 24 of 107 patients (22.4%) receiving ketamine and 27 of 107 (25.2%) receiving placebo (95% CI for difference, −14% to 9%). There were no differences between arms among the secondary outcomes (Table).

There were 18 serious adverse events: 8 in patients receiving ketamine and 10 in patients receiving placebo. Common adverse events were cognitive disturbance, dizziness, fatigue, nausea, and somnolence.

**Discussion**  This trial reports that ketamine was equivalent to placebo for cancer-related neuropathic pain. Findings enhance previous work by examining ketamine in cancer-related neuropathic pain. There may be subgroups of patients for whom ketamine is helpful, such as those with central sensitization. A limitation of the present study was that we did not specifically select patients with clinical evidence of central sensitization, for whom it is reasonable to hypothesize a more specific analgesic target for ketamine. Future studies that examine ketamine in chronic neuropathic pain should focus on patients with central sensitization, which can be established by a bedside test. This approach would be congruent with preclinical knowledge and would address an important remaining unanswered question.

Marie T. Fallon, MD
Andrew Wilcock, MD
Caroline A. Kelly, MSc
James Paul, BSc
Liz-Anne Lewsley, CCR
John Norrie, MSc
Barry J. A. Laird, MD

**Author Affiliations:** Edinburgh Cancer Research Centre (IGMM), University of Edinburgh, Edinburgh, United Kingdom. (Fallon, Laird); Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, United Kingdom (Wilcock); Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom (Kelly, Paul, Lewsley); Usher Institute, University of Edinburgh, Edinburgh, United Kingdom (Norrie).

**Accepted for Publication:** January 11, 2018.

**Published Online:** April 5, 2018. doi:10.1001/jamaoncol.2018.0131

**Open Access:** This is an open access article distributed under the terms of the CC-BY License. © 2018 Fallon MT et al. JAMA Oncology.

**Corresponding Author:** Marie T. Fallon, MD, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XR, UK (marie.fallon@ed.ac.uk).

**Author Contributions:** Drs Fallon and Laird had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Fallon, Paul, Laird. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: Fallon, Wilcock, Kelly, Paul, Lewsley, Laird.

**Critical revision of the manuscript for important intellectual content:** Fallon, Wilcock, Kelly, Paul, Norrie, Laird

**Statistical analysis:** Fallon, Wilcock, Kelly, Paul, Norrie, Laird

**Obtained funding:** Fallon, Paul, Lewsley, Laird

**Administrative, technical, or material support:** Fallon, Paul, Lewsley, Laird

**Study supervision:** Fallon, Paul.

**Conflict of Interest Disclosures:** None reported.

**Funding/Support:** This trial was funded by grant 07/031 from Cancer Research UK and grant A14197 from Marie Curie Cancer Care. The University of Glasgow and NHS Greater Glasgow and Clyde acted as cosponsors. The medicines used in this trial (ketamine hydrochloride for the investigational medicinal product, and lactose [in powder form]) and placebo for the placebo were purchased and were manufactured into a capsule formulation by the NHS Greater Glasgow and Clyde Pharmacy Production Unit.

**Role of the Funder/Sponsor:** The funders had no role beyond peer review for the grants. Annual reports were submitted to the funders to enable continued funding. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Additional Contributions:** We wish to thank the Ketamine Pain Study Group: S. M. Fleetwood-Walker, PhD, University of Edinburgh, basic science translational research collaborator; Dian Taggart, BSc, University of Glasgow, trial coordinator; and Dorothy Boyle, BSc, University of Edinburgh; Anne Todd, BA NHS Greater Glasgow and Clyde; and Alison Clarke, RGN, University of Sheffield, research nurses. Anne Todd; Dorothy Boyle; Catherine Johnston, MSc, NHS Greater Glasgow and Clyde; Debra Gordon, BSc, University of Edinburgh; Kim Sladden, MA Hons, RGN, University of Edinburgh; Lisa Ferguson, RGN, Oxford University Hospitals NHS Foundation Trust; and Cathann Manderson, RGN, Nottingham University Hospitals NHS Trust, participated in data collection for this study. Miriam Johnson, MD, University of Hull; Dena Cohen, PhD, University of Leeds; and Sara Booth, MD, University of Cambridge, served as the data monitoring committee; Anthony Byrne, MB ChB, University of Cardiff; Tom Haswell; John Wilson, MD, University of Edinburgh; Bee Wee, PhD, University of Oxford; and Gareth Griffiths, PhD, University of Southampton, served as the trial steering committee; and Lesley Colvin, PhD, University of Edinburgh; Michael Bennett, MD, University of Leeds; Kay Pollock, BSc, Pharmacy Production Unit, NHS Greater Glasgow and Clyde; Catherine Urch, PhD, Imperial College, London; John Welsh, MB ChB, St Margaret of Scotland Hospice/University of Glasgow; Alison Parr, MB ChB, St Catherine’s Hospice, Preston; and Patrick Stone, MD, University of London, served as research collaborators. They were not compensated for their contributions. We also wish to thank our colleagues at the sites where the trial was conducted for their support, particularly the Cancer Research UK Clinical Trials Unit, Glasgow. Finally, this trial would not have been possible without the support of the patients who participated.